Despite existing treatments, patients with heart failure and chronic kidney disease (CKD)
remain at high risk for adverse outcomes and progression to end-stage disease. Steroidal …

Since 2006, the Canadian Cardiovascular Society heart failure (HF) guidelines have
published annual focused updates for cardiovascular care providers. The 2010 Canadian …

Background Chronic heart failure is associated with high mortality and morbidity. Raised
resting heart rate is a risk factor for adverse outcomes. We aimed to assess the effect of heart …

Aims To assess physicians' adherence to guideline‐recommended medications for the
treatment of chronic heart failure (CHF) with reduced ejection fraction. Methods and results …

AIM: Patients with heart failure (HF) have reduced exercise capacity. The beneficial effect of
beta-blocker on prognosis is not matched by an impact on exercise capacity and quality of …

Aims Contemporary patterns of care of patients with chronic kidney disease (CKD)
associated with type 2 diabetes (T2D) and the adoption of finerenone are not known. The …

Abstract Background In the Studies of Left Ventricular Dysfunction (SOLVD) treatment trial,
similar clinical benefits were observed between starting doses of enalapril and the target …

Chronic kidney disease (CKD) is one of the most common complications of diabetes mellitus
and an independent risk factor for cardiovascular disease. Despite guideline-directed …

OBJECTIVES: To conduct an integrative review that explores the experiences and
perceptions of patients who have heart failure to find any commonality that might enhance …

Aims Elevated heart rate is a significant marker for mortality and morbidity in cardiovascular
disease including heart failure. Despite background treatment with a beta‐blocker, many …